WallStSmart

Harrow Health Inc (HROW)vsTeva Pharma Industries Ltd ADR (TEVA)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 6183% more annual revenue ($17.32B vs $275.59M). TEVA leads profitability with a 4.1% profit margin vs -13.5%. TEVA earns a higher WallStSmart Score of 46/100 (D+).

HROW

Avoid

23

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: 0.76

TEVA

Hold

46

out of 100

Grade: D+

Growth: 5.3Profit: 5.0Value: 5.0Quality: 3.5
Piotroski: 6/9Altman Z: 0.28

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HROW0 strengths · Avg: 0/10

No standout strengths identified

TEVA2 strengths · Avg: 9.0/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

PEG RatioValuation
0.718/10

Growing faster than its price suggests

Areas to Watch

HROW4 concerns · Avg: 2.3/10
Market CapQuality
$1.41B3/10

Smaller company, higher risk/reward

Price/BookValuation
80.7x2/10

Trading at 80.7x book value

Return on EquityProfitability
-35.4%2/10

ROE of -35.4% — below average capital efficiency

EPS GrowthGrowth
-10.3%2/10

Earnings declined 10.3%

TEVA4 concerns · Avg: 2.5/10
Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Operating MarginProfitability
4.0%3/10

Operating margin of 4.0%

P/E RatioValuation
65.0x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-0.8%2/10

Revenue declined 0.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : HROW

Revenue growth of 10.9% demonstrates continued momentum.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.71 suggests the stock is reasonably priced for its growth.

Bear Case : HROW

The primary concerns for HROW are Market Cap, Price/Book, Return on Equity. Debt-to-equity of 19.79 is elevated, increasing financial risk.

Bear Case : TEVA

The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 65.0x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.

Key Dynamics to Monitor

HROW profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.

TEVA carries more volatility with a beta of 0.80 — expect wider price swings.

HROW is growing revenue faster at 10.9% — sustainability is the question.

TEVA generates stronger free cash flow (307M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (46/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Harrow Health Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?